Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12621 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Sherry Rohekar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Magnetic Resonance Imaging, Spondylarthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SPARCC Research Pilot Project Program.
Abstract (Originalsprache)
Background
A temporal relationship between vedolizumab and new‐onset spondyloarthritis (SpA) has been suggested.
Aims
We evaluated the relationship between vedolizumab initiation and development of new‐onset SpA in patients with inflammatory bowel disease (IBD) through serial clinical evaluation and magnetic resonance imaging (MRI).
Methods
A single‐centre prospective observational study of 24 patients with IBD. Patients were eligible if they had active ulcerative colitis or Crohn's disease (CD), were initiating vedolizumab, had no prior history of arthritis or SpA and were suitable for serial MRI. A rheumatologist performed clinical evaluation prior to the first dose and 8 and 24 weeks. Axial MRI was evaluated by a blinded central reader and performed at baseline 8 and 24 weeks.
Results
Nine tumor necrosis factor (TNF) inhibitor‐naïve patients (4 male; mean age 53.2 years; 6 UC; 3 CD) and eight TNF inhibitor‐experienced patients (7 male; mean age 48 years; 3 UC; 5 CD) completed all assessments. No patients developed new features of axial arthritis or features of peripheral SpA (inflammatory oligoarthritis, enthesitis, dactylitis, or psoriasis (nail, body, or scalp)). Both groups demonstrated a good intestinal response.
Conclusion
Vedolizumab initiation did not induce new features of axial or peripheral SpA after 24 weeks of treatment in TNF inhibitor‐experienced or TNF inhibitor‐naive patients with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Rheumatology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
- Lawson Health Research Institute, London, Ontario, Canada.
- Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.
- Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
- Southwestern Ontario Inflammatory Bowel Disease Clinic, London, Ontario, Canada.
- London Health Sciences Centre, London, Ontario, Canada.
ORCID-Profile: Trimadhu Sharma, Vipul Jairath
Förderung
- SPARCC Research Pilot Project Program
Zitieren
APA
Rohekar, S., Boyd, T., Lambert, R. G., Beaton, M., Chande, N., Gregor, J., Lennox, H., Mcintosh, K., Ponich, T., Rahman, A., Sharma, T., Sey, M., Tauqir, M., & Jairath, V. (2024). Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12621
Vancouver
Rohekar S, Boyd T, Lambert RG, Beaton M, Chande N, Gregor J, et al. Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12621
BibTeX
@article{Rohekar2024,
author = {Rohekar, Sherry and Boyd, Tristan and Lambert, Robert G and Beaton, Melanie and Chande, Nilesh and Gregor, Jamie and Lennox, Heather and Mcintosh, Keith and Ponich, Terry and Rahman, Adam and Sharma, Trimadhu and Sey, Michael and Tauqir, Maria and Jairath, Vipul},
title = {Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12621}
}
EUVIMED